Since these were likely caused by repression of the MSH6-CXCR4-TGF-β1 feedback loop and its downstream targets, this TGF-β1 involving circuit emerges as a novel and promising therapeutic target in GBM [106]. The gene discussed is MSH6; the disease is glioblastoma.